Lecap Asset Management Ltd. Sells 5,863 Shares of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN)

Lecap Asset Management Ltd. cut its stake in BioMarin Pharmaceutical Inc. (NASDAQ:BMRN - Free Report) by 40.8% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 8,492 shares of the biotechnology company's stock after selling 5,863 shares during the quarter. Lecap Asset Management Ltd.'s holdings in BioMarin Pharmaceutical were worth $558,000 as of its most recent SEC filing.

Other institutional investors have also modified their holdings of the company. nVerses Capital LLC acquired a new stake in shares of BioMarin Pharmaceutical during the third quarter valued at about $28,000. TD Private Client Wealth LLC increased its holdings in BioMarin Pharmaceutical by 57.4% in the 3rd quarter. TD Private Client Wealth LLC now owns 510 shares of the biotechnology company's stock valued at $36,000 after purchasing an additional 186 shares during the last quarter. Meeder Asset Management Inc. raised its position in BioMarin Pharmaceutical by 920.8% in the third quarter. Meeder Asset Management Inc. now owns 735 shares of the biotechnology company's stock valued at $52,000 after purchasing an additional 663 shares during the period. GAMMA Investing LLC lifted its stake in BioMarin Pharmaceutical by 56.1% during the third quarter. GAMMA Investing LLC now owns 782 shares of the biotechnology company's stock worth $55,000 after purchasing an additional 281 shares in the last quarter. Finally, True Wealth Design LLC grew its stake in shares of BioMarin Pharmaceutical by 13,400.0% in the third quarter. True Wealth Design LLC now owns 810 shares of the biotechnology company's stock valued at $57,000 after buying an additional 804 shares in the last quarter. Hedge funds and other institutional investors own 98.71% of the company's stock.

BioMarin Pharmaceutical Stock Up 3.6 %

NASDAQ:BMRN traded up $2.31 on Wednesday, hitting $65.86. 1,187,703 shares of the company's stock traded hands, compared to its average volume of 1,526,225. The firm has a 50-day moving average price of $64.95 and a 200-day moving average price of $71.78. The company has a current ratio of 4.27, a quick ratio of 2.62 and a debt-to-equity ratio of 0.11. The company has a market cap of $12.55 billion, a PE ratio of 39.44, a price-to-earnings-growth ratio of 0.57 and a beta of 0.28. BioMarin Pharmaceutical Inc. has a 1 year low of $60.63 and a 1 year high of $94.85.

Analysts Set New Price Targets

A number of equities analysts recently commented on BMRN shares. William Blair cut BioMarin Pharmaceutical from an "outperform" rating to a "market perform" rating in a report on Wednesday, October 30th. StockNews.com raised shares of BioMarin Pharmaceutical from a "buy" rating to a "strong-buy" rating in a research note on Tuesday. UBS Group raised their price target on shares of BioMarin Pharmaceutical from $104.00 to $106.00 and gave the company a "buy" rating in a research report on Wednesday, October 30th. Cantor Fitzgerald reiterated an "overweight" rating and issued a $90.00 price objective on shares of BioMarin Pharmaceutical in a research note on Thursday, December 12th. Finally, Robert W. Baird reduced their price target on BioMarin Pharmaceutical from $72.00 to $65.00 and set a "neutral" rating on the stock in a research report on Wednesday, October 30th. Seven research analysts have rated the stock with a hold rating, fifteen have given a buy rating and two have given a strong buy rating to the company's stock. According to MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $94.20.

BioMarin Pharmaceutical Company Profile

BioMarin Pharmaceutical Inc develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form of 6R-BH4 that is used to treat patients with phenylketonuria (PKU), an inherited metabolic disease.